KEY DETAILS
STAT reports that telehealth startups Quel, Livelyhood and Choose Your Horizon are marketing off-label GLP-1 prescriptions to people struggling with substance use.
CBS News reports that roughly 54% of people taking semaglutide drugs like Ozempic and Wegovy use them for weight loss, overtaking other medical reasons, per EY-Parthenon.
12onyourside.com reports that Eli Lilly broke ground Thursday on a $5 billion manufacturing facility in Goochland County, expected to bring about 1,800 construction jobs and 650 permanent positions.
Aol.com reports that a Trump administration agreement last year with Eli Lilly and Novo Nordisk lowered the cost of Ozempic and Wegovy to between $150 and $350 per month, down from roughly $1,000.
Fool.com reports that Eli Lilly's FY2025 revenue reached roughly $65.2 billion, fueled by a 45% year-over-year sales increase.
Eli Lilly broke ground Thursday on a $5 billion manufacturing facility in Goochland County, 12onyourside.com reports. STAT reports that telehealth startups Quel, Livelyhood and Choose Your Horizon are marketing off-label GLP-1 prescriptions to people struggling with substance use.
STAT reports that Quel, Livelyhood and Choose Your Horizon are marketing off-label prescriptions of GLP-1 obesity drugs to people struggling with substance use. According to STAT, these drugs are showing promise as treatments for addiction, particularly alcohol use disorder, and some telehealth companies are not waiting for the FDA to weigh in. STAT also reports that the companies are sometimes offering compounded versions that have not been approved by regulators.
CBS News reports that more Americans are now taking GLP-1 drugs to lose weight than to treat diabetes and the other conditions the medications were originally prescribed for. The outlet cites EY-Parthenon research showing that roughly 54% of people taking semaglutide drugs like Ozempic and Wegovy use them to lose weight, overtaking the share who use them for other medical reasons. CBS News also reports that 63% of GLP-1 users say they have reduced their consumption of sweet snacks, while 57% say they eat fewer salty snacks, according to the same research.
12onyourside.com reports that Eli Lilly broke ground Thursday on a $5 billion manufacturing facility in Goochland County's West Creek area. The outlet reports the facility is expected to bring approximately 1,800 construction jobs to the region, followed by 650 permanent positions once manufacturing operations begin. According to 12onyourside.com, the Goochland project is part of Eli Lilly's broader $50 billion commitment to expand pharmaceutical manufacturing in the United States, and the company's rapid growth has been fueled in part by demand for Mounjaro and Zepbound. The outlet reports the company expects construction to be completed by 2030.
Aol.com reports that a Trump administration agreement last year with Eli Lilly and Novo Nordisk lowered the cost of Ozempic and Wegovy to between $150 and $350 per month, down from roughly $1,000 per month.
Fool.com reports that Eli Lilly's FY2025 revenue reached roughly $65.2 billion, fueled by a 45% year-over-year increase in sales. The outlet reports that revenue is expected to climb more than a third in 2026, to $88.7 billion, with close to $31 billion in net income.
You can find the full details on the off-label marketing story at STAT, the usage shift at CBS News and Aol.com, the Goochland groundbreaking at 12onyourside.com, and Eli Lilly's financial outlook at Fool.com.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.